期刊论文Lurbinectedin (PM01183) synergizes in vivo the antitumor activity of doxorubicin in SCLC tumor xenografts复制

DOI:复制

文献链接:复制

其他信息:

MJ Guillen, O Cataluña, M Palomares, R Lopez…
Cancer …, 2015
aacrjournals.org
Abstract Background: Lurbinectedin (PM01183) is a synthetic tetrahydroisoquinoline alkaloid currently evaluated as single agent and in combination in phase I and II clinical trials for solid tumors and hematological malignancies. In living cells, PM01183-DNA adducts stall replication and transcription giving rise to double strand breaks, inducing accumulation of cells in the S-phase of the cell cycle and triggering apoptosis. Studies aimed at defining the in vivo synergism of PM01183 and doxorubicin in the treatment of …